Hla Group Corp., Ltd.

600398

CNE0000016H3

HLA GROUP CORP LTD, formerly Hla Corp Ltd, is a China-based company, principally engaged in the operation of branded garments, and the production and sales of high-end suits and business wear. The operations of branded garments include the management of brands, supply chains and marketing networks. The Company provides pants, T shirts, western-style clothes, down jacket, jackets, knitwear and others. The Company distributes its products mainly in domestic markets.

Sector

Apparel & Accessories

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Hla Group Corp., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.83 CNY

Average target price

9.234 CNY

Spread / Average Target

+4.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Men's Clothing

	1st Jan change	Capi.
HLA GROUP CORP., LTD.	+19.00%	6.08B
BAOXINIAO HOLDING CO., LTD.	+2.82%	1.12B
JOEONE CO.,LTD	+3.11%	797M
JIANGSU HONGDOU INDUSTRIAL CO.,LTD	-3.94%	793M
CHINA LILANG LIMITED	+9.22%	727M
THOB AL ASEEL COMPANY	+7.89%	539M
FUJIAN SEPTWOLVES INDUSTRY CO., LTD.	-0.17%	540M
SUPERIOR GROUP OF COMPANIES, INC.	+24.74%	282M
CREDO BRANDS MARKETING LIMITED	-36.83%	144M
ZHEJIANG BUSEN GARMENTS CO., LTD.	-34.97%	99.76M

Men's Clothing

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
8.83 ^CNY	-3.71%		-6.06%	+19.00%

Apr. 11	Ose Immuno receives funding from Bpifrance	CF
Mar. 19	HLA to Redeem Convertible Bonds Early	MT

Ose Immuno receives funding from Bpifrance	Apr. 11	CF
HLA to Redeem Convertible Bonds Early	Mar. 19	MT
Diamyd Medical Secures US FDA Fast Track Designation for Type 1 Diabetes Treatment	Feb. 15	MT
OSE Immuno: collaboration agreement with GenDx	Nov. 21	CF
Diamyd Medical Partners With DiaUnion for Diabetes Drug Trial	Nov. 07	MT
Hla Group Corp., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Diamyd Medical Reports Updated Data on Subcutaneous Treatment to Delay Type 1 Diabetes Onset in Kids	23-10-26	MT
Immatics' IMA203 TCR-T Program Receives Regenerative Medicine Advanced Therapy Designation	23-10-24	MT
Diamyd Medical’s Diabetes Drug Shows Booster Safety in Mid-stage Study; Shares Jump	23-10-20	MT
IDEAYA Biosciences Initiates Phase 2 Expansion of Combination Therapy for Metastatic Cutaneous Melanoma	23-10-16	MT
Healthia Expands North American Laboratory Operations	23-10-12	MT
Hla Group Corp., Ltd.(XSSC:600398) added to S&P Global BMI Index	23-09-18	CI
Hla Group Corp., Ltd.(XSSC:600398) added to FTSE All-World Index	23-09-18	CI
OSE Immunotherapeutics' Lung Cancer Vaccine Extends Survival in Late-stage Study	23-09-12	MT
China Manufacturing Gloom Tempers Gains of Australian Equities	23-08-31	MT
Healthia Receives AU$260 Million Acquisition Bid from Pacific Equity Partners	23-08-31	MT
Hla Group Corp., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
BriaCell Therapeutics Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer	23-08-16	MT
Marker Therapeutics Says Non-clinical Data Show MT-401 Inducing Anti-tumor Activity in Specific Setting	23-08-07	MT
OSE Immunotherapeutics Wins Cancer Vaccine Patent in US	23-07-05	MT
OSE Immuno: receives 1.5 ME funding from Bpifrance	23-06-20	CF
Hla Group Corp., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Healthia Settles Acquisitions of Clinics, Optical Stores in Victoria	23-03-23	MT
Diamyd Medical Expects to Close Enrolment for Diabetes Drug Trial by Summer 2024	23-02-20	MT
OSE Immunotherapeutics Wins US FDA's Backing for Late-stage Development of Cancer Vaccine Candidate	23-02-15	MT